Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsAvMed Vyleesi (bremelanotide) Prior Auth | OpenPay…
    Ask Trek AI about this page
    CurrentAvMedPolicy N/A

    Prior authorization and coverage criteria for Vyleesi (bremelanotide)

    Customize your policy alerts

    Sign up for all AvMed policy alerts

    Know when AvMed releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This document is a prior authorization/step-edit request form and clinical criteria for coverage of Vyleesi (bremelanotide) for members of AvMed. It governs prescriber submission requirements and clinical eligibility for Vyleesi therapy.

    Policy Summary
    PayerAvMed
    PolicyPrior authorization and coverage criteria for Vyleesi (bremelanotide)
    Policy CodePolicy N/A
    Change TypeNo material clinical or coverage changes
    Effective DateN/A
    Last ReviewJul 26, 2023
    Next Review DateN/A
    Key ActionSubmit a completed prior authorization with prescriber signature, required patient/prescriber details, documentation of an unsuccessful 8‑week Addyi trial, and supporting chart notes to avoid denial.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    8 dosesquantity limit per 30 days
    >=18minimum age requirement
    6 monthssymptom duration

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    8-weekrequired failed trial
    No uncontrolled CV diseasecardiovascular exclusion

    Coverage Criteria

    Initial Authorization

    Covered when ALL of the following are met

    Vyleesi PA criteria: Member is pre-menopausal; Member is 18 years of age or older; Member has a diagnosis of Hypoactive Sexual Desire Disorder (HSDD) with symptoms that have persisted for at least 6 months; Member's HSDD is not related to any other medical or psychiatric condition, substance abuse, or relationship issue; Member has had an unsuccessful 8-week trial of Addyi (flibanserin) documented (chart notes or pharmacy claims); The prescribing physician has determined and documented the average pre-treatment number of satisfying sexual events for the patient to evaluate treatment efficacy; Member does not have uncontrolled hypertension or known cardiovascular disease; Use is limited to no more than 8 doses per 30 days and no more than one dose within a 24-hour time frame.all must be met

    To support each checked criterion, provide documentation (labs, diagnostics, chart notes, or pharmacy paid claims) as applicable.

    Documentation requirements

    • Prescribing physician must sign and clearly print name on the request form (preprinted stamps not valid).
    • Include member and prescriber information, drug form/strength, dosing schedule, length of therapy, diagnosis with ICD code, weight, and date as requested on the form.
    • Chart notes must document an unsuccessful 8-week trial of Addyi if claimed; pharmacy paid claims may be used to verify previous therapies.

    Coverage for Vyleesi (bremelanotide) excludes members with uncontrolled hypertension or any known cardiovascular disease. This cardiovascular safety exclusion must be assessed and documented prior to authorization; members meeting either condition are not eligible under the policy.

    Initial Therapy

    Initial Therapy

    Covered when ALL of the following are met

    Initial therapy criteria: Member is pre-menopausal; Age 18 years or older; Diagnosis of Hypoactive Sexual Desire Disorder (HSDD) with symptoms persisting at least 6 months causing marked distress or interpersonal difficulty; HSDD not attributable to other medical/psychiatric conditions, substance abuse, or relationship issues; Documented unsuccessful 8-week trial of Addyi (flibanserin); Prescriber has recorded the average pre-treatment number of satisfying sexual events to establish baseline; No uncontrolled hypertension or known cardiovascular disease; Limit therapy to no more than 8 doses per 30 days and no more than one dose within any 24-hour period.all must be met

    Chart notes, diagnostics, labs, and/or pharmacy claims must be provided to support each criterion; prior authorization form must be complete and signed by the prescribing physician.

    Provider Submission & Actions

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required. All clinical criteria must be documented and submitted with the request; incomplete or illegible information may delay processing or cause denial.

    • Fax completed form to 1-305-671-0200
    • Prescriber signature (preprinted stamps not valid) is required
    • Include phone and fax numbers for office contact
    Step Therapy

    Step Therapy Requirement

    An unsuccessful 8-week trial of Addyi (flibanserin) is required prior to approval. Documentation of the prior trial must be submitted.

    • Chart notes documenting the trial and lack of response, or
    • Paid pharmacy claims showing prior Addyi fills that indicate treatment and lack of effectiveness

    Coding & Related Criteria

    Quantity limitsNDC | internalCovered
    Quantity Limit: 8 doses (2.4 mL) per 30 daysSpecified quantity limit for Vyleesi
    inv-04: Symptom duration for HSDD
    Minimum symptom duration6 months
    ContextApplies to diagnosis of Hypoactive Sexual Desire Disorder (HSDD) with symptoms persisting at least 6 months
    DocumentationChart notes or other documentation supporting symptom duration must be provided

    Quantity Limits

    inv-15: Vyleesi (bremelanotide) — quantity limit
    Quantity limit (per 30 days)8 doses (2.4 mL)
    Maximum dosing frequencyNo more than one dose within a 24-hour time-frame
    Documentation noteUse limited to <=8 doses per month must be documented on authorization form

    Step Therapy Requirements

    StepRequirement
    1Documented unsuccessful 8-week trial of Addyi (flibanserin) with chart notes or pharmacy paid claims submitted to verify failure

    Definitions

    inv-12: HSDD definition — Hypoactive Sexual Desire Disorder
    DefinitionHypoactive Sexual Desire Disorder (HSDD): low sexual desire that causes marked distress or interpersonal difficulty
    Duration criterionSymptoms have persisted for at least 6 months
    Attribution criterionHSDD is not related to other medical or psychiatric conditions, substance abuse, or relationship issues
    PopulationApplies to premenopausal members aged 18 years or older when other criteria are met

    Background

    Vyleesi (bremelanotide) is indicated for treatment of Hypoactive Sexual Desire Disorder (HSDD) in premenopausal women. This prior authorization form captures clinical eligibility and documentation requirements to determine coverage, including baseline measurement of satisfying sexual events, verification of an unsuccessful 8-week trial of Addyi (flibanserin) when applicable, and limits on dosing. The form is used to confirm that the member is premenopausal, at least 18 years of age, has HSDD symptoms for the required duration, does not have excluded cardiovascular conditions, and will not exceed the dosing limit of 8 doses per 30 days or more than one dose in 24 hours.

    Policy Summary
    PayerAvMed
    PolicyPrior authorization and coverage criteria for Vyleesi (bremelanotide)
    Policy CodePolicy N/A
    Change TypeNo material clinical or coverage changes
    Effective DateN/A
    Last ReviewJul 26, 2023
    Next Review DateN/A
    Key ActionSubmit a completed prior authorization with prescriber signature, required patient/prescriber details, documentation of an unsuccessful 8‑week Addyi trial, and supporting chart notes to avoid denial.
    SourceLink
    On This Page
    Coverage CriteriaInitial TherapyProvider Submission & ActionsCoding & Related CriteriaQuantity LimitsStep Therapy RequirementsDefinitionsBackground
    Documentation Required

    Required Submission Information

    Provide complete prescriber and patient information and drug details. Missing fields or illegible entries may delay or jeopardize the authorization.

    • Prescriber signature and date (required)
    • Member name, AvMed ID, and date of birth
    • Prescriber name, DEA or NPI number, office contact, phone and fax
    • Drug form/strength, dosing schedule, length of therapy, quantity requested
    • Diagnosis and ICD code, patient weight, and relevant chart notes/labs
    Denial Risk

    Clinical Criteria Unmet — Denial Risk

    If clinical criteria are not all met or documented, the request may be denied.

    • Member must be pre-menopausal and ≥ 18 years old
    • Diagnosis of HSDD with symptoms for ≥ 6 months and causing marked distress or interpersonal difficulty
    • HSDD not secondary to other medical/psychiatric conditions, substance abuse, or relationship issues
    • Documented unsuccessful 8-week trial of Addyi
    • No uncontrolled hypertension or known cardiovascular disease
    • Limit use to ≤ 8 doses per month and no more than one dose in 24 hours